Christopher R. Cline - 31 Jan 2026 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: TVTX
Reported as of: 31 Jan 2026
Net transaction value: -$232,613
SEC form: 4
Accepted by SEC: 03 Feb 2026, 21:30:12 UTC
Prior SEC filing: 03 Dec 2025
Next SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

Christopher R. Cline filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 03 Feb 2026.

Key facts

This page summarizes Christopher R. Cline's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2026, 21:30.

Change

Previous filing in this sequence was filed on 03 Dec 2025.
Current net transaction value: -$232,613.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001943192 Primary reporting owner

Cline Christopher R.

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Signature date: 03 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Award

Transaction value: $0
Shares: +28,130
Change %: +31%
Price: $0.000000
Shares after: 120,213
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F1

TVTX transaction

Common Stock

Sale

Transaction value: $232,613
Shares: -7,242
Change %: -6%
Price: $32.12
Shares after: 112,971
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TVTX transaction Derivative

Employee stock option (right to buy)

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 75,000
Date: 31 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $33.10
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Footnote F2

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Footnote F3

One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.